Capricor disputes FDA briefing materials for Deramiocel as based on outdated plan

 

Capricor disputes FDA briefing materials for Deramiocel as based on outdated statistical analysis plan

• Company says FDA used an outdated statistical analysis plan in Deramiocel briefing materials for July 29 advisory committee.
• Capricor posts portions of its July 29 advisory committee presentation slides on its website for investors.
• Slides highlight statistically significant HOPE-3 results that Capricor says support Deramiocel’s efficacy.

https://finviz.com/stock?t=CAPR&p=d